The overall aim of this observational study is to evaluate Patient Reported Outcomes (PROs), including Health-related Quality of Life (HRQoL), and to describe characteristics of psoriatic arthritis (PsA) and axial spondylitis (axSpA) (nonradiographic [nr]-axSpA and radiographic [r]-axSpA) patients following bimekizumab treatment initiation over time in routine clinical practice. To improve medical care continuously, it is thus very important to collect further data on the use of a drug outside of regulated clinical trials. The purpose of this study is • to observe ...

GO TO STUDY

Hospital-acquired thrombosis (HAT) is defined as any VTE within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key ...

GO TO STUDY

Inherited Cardiac Conditions (ICCs) are a collection of medical disorders that are associated with life-threatening heart rhythm and heart muscle adnormalities. They demonstrate a familial tendency, and a number of disease-causing gene mutations have already been identified. However, a significant proportion of affected families remain with no associated disease-causing mutation; some families have unexplained differences in the severity or type of disorder that different individuals with the same mutation demonstrate. This represents a knowledge gap that this study aims to ...

GO TO STUDY

This Phase III, multi-center, open-label, sponsor-blinded, randomized study is designed to evaluate the efficacy and safety of AZD0901 compared to Investigator’s choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2, and the clinical performance of the investigational IVD. As part of this combined approach, t he efficacy analyses from this study will also provide the basis to evaluate the clinical performance of Ventana CLDN18.2 (SP455) IHC assay (prototype assay and/or validated assay ...

GO TO STUDY

BI 690517 is an aldosterone synthase inhibitor and participants will be randomised 1:1 (using a minimisation algorithm) to active of placebo BI 690517 in addition to study supplied empagliflozin 10mg daily.

GO TO STUDY

Approximately 420 eligible participants will be randomized in a 1:1 ratio to aficamten or placebo. Doses of 5, 10, 15, or 20 mg aficamten or matching placebo will be administered in an escalating manner using echocardiography to guide dose titration. Randomization will be stratified by persistent atrial fibrillation and presence of intracavitary obstruction. The study will consist of 2 parts: Part 1 will be comprised of Day 1 to Week 36 and Part 2 will be comprised of Week 36 to ...

GO TO STUDY

This is a Phase II, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in patients with active moderate to severe UC, including 1) patients who have demonstrated inadequate response to, loss of response to, or intolerance to prior advanced therapy which includes biologics and targeted small molecules (advanced failures), and 2) patients who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional therapies (corticosteroids and/or ...

GO TO STUDY

Behçet's disease (BD) is an inflammatory condition that causes damages of the blood vessels affecting many parts of the body. The disease is characterized by intermittent symptoms of varying severity across almost all organ systems and oral ulcers, considered the most common sign at the onset of BD and are observed in nearly every patient The treatment of BD is generally based on experience, and the drug of choice is based on specific clinical signs and symptoms in each patient. The ...

GO TO STUDY

This research aims to determine the quality-of-life (healthcare-related utility scores) following surgery to remove the womb (hysterectomy) to prevent endometrial cancer. We will use this information to build a model to determine the level of lifetime risk of endometrial cancer at which this preventive surgery is cost-effective. Finally, we will assess the acceptability of offering preventive hysterectomy to general population women at or around these risk thresholds determined. Part 1 is a cross-sectional cohort survey study of women with Lynch ...

GO TO STUDY

This is a multicentre, prospective, non-interventional observational cohort study of patients who are planned to receive, or already receiving Epidyolex under real-world conditions of clinical care. This study is designed to address a Pharmacovigilance Risk Assessment Committee (PRAC) request to conduct a Category 3 Post-Authorisation Safety Study (PASS), as requested in the Risk Management Plan (RMP) at the time of approval. While 12 safety concerns were noted in the RMP, PRAC emphasis was on the need to further characterize the ...

GO TO STUDY